Insights

The New Gold Standard of Drug Commercialization

Manufacturers spend >$125MM over three years leading up to launch, yet 66% of drugs don’t meet launch expectations. An unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach…

Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard

The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma…

A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes

Today we have access to more data, from more sources than we could ever dream possible. Living in a digital world, we increasingly need the ability to efficiently and effectively process this data for insights and…

Why are We Settling for Mediocre Patient Services Programs?

Patient Services Programs Are Falling Short To give credit where credit is due, pharmaceutical manufacturers make a tremendous – and well-intended – effort to alleviate the product access obstacles and burdens patients and providers often endure…

Articles

CMS Adopts Automatic Medicare Coverage of Breakthrough Devices

The Centers for Medicare and Medicaid Services (CMS) on January 12 finalized its proposal of Medicare Coverage of Innovative Technology (MCIT), an additional pathway of coverage for breakthrough-designated medical devices, providing timelines and clarifying definitions of…

COVID-19 Vaccine Safety Briefing Report

As the world awaits the fast-approaching rollout of an approved COVID-19 vaccine, developing the planning to order, distribute and track COVID-19 vaccines in the United States and globally presents an unprecedented challenge. The Food and Drug…

A New Pharmaceutical Strategy for Europe

In late November, the European Commission announced the adoption of a new healthcare plan – the Pharmaceutical Strategy for Europe. This plan aims to strengthen the European Health Union while ensuring affordable patient access across the…

What Happens After a COVID-19 Vaccine Trial Succeeds? 4 Pharmacovigilance Challenges to Address During Commercialization

As we near the end of 2020, we might also be near an end to the widespread illness caused by the COVID-19 pandemic. With two vaccine trials currently leading the way and more than 50 others…

Managing Risks to Improve Health Outcomes: How to Move Population Health Forward in an Era of Uncertainty

At the Canadian Association for Population Therapeutics (CAPT) Annual Conference, Sumeet Singh, Senior Director, EVERSANA, delivered a presentation on pharmacoeconomic analysis and outcome-based agreements and what they mean for Canadian private payers. Watch his session below…

Leadership Briefing – The U.S. Pharmaceutical Market Outlook: The Path to Recovery and the New Normal

With the U.S. presidential election days away and the continued impact of a pandemic, EVERSANA and Reuters gathered industry leaders to discuss what is to come. Watch as the panel discusses the tough questions facing pharma,…

An Illustration: Transforming the Patient Experience

As a fierce ally of the rare disease community, EVERSANA proudly sponsored the 2020 Rare Diseases & Orphan Products Breakthrough Summit. Longtime partners in the advancement of orphan drug commercialization, EVERSANA and the National Organization for…

eBook – 2020 Stories That Shaped Commercialization

While many industries hit the pause button on their operations this year, the pharmaceutical industry never stopped, propelling new innovations to better serve patients, providers and stakeholders. At EVERSANA, we worked closely with manufacturers to tackle…

Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard

The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma…

WODC 2020 Insights: Innovative Value and Access Strategies

Innovative rare disease therapies deserve innovative value and access strategies.  With over 1,500 attendees from 50+ countries, the World Orphan Drug Congress featured four days of education, conversation and brainstorming dedicated to drug development and commercialization.…